open access

Vol 59, No 2 (2008)
Original papers
Published online: 2008-05-08
Submitted: 2013-02-15
Get Citation

Influence of the endogene TSH stimulation of thyroid volume increase in the patients after total thyroidectomy due to differentiated thyroid cancer

Leszek Pietz, Krzysztof Michałek, Ryszard Waśko, Marek Ruchała, Jerzy Sowiński
Endokrynologia Polska 2008;59(2):119-122.

open access

Vol 59, No 2 (2008)
Original papers
Published online: 2008-05-08
Submitted: 2013-02-15

Abstract


Introduction: The treatment-of-choice for differentiated thyroid carcinoma (DTC) is a total thyroidectomy with subsequent radioiodine therapy. In order to increase an iodine uptake in thyroid tissue remnants, the L-thyroxine withdrawal is required. It is recommended to achieve TSH levels higher than 25 mU/ml. As TSH is a known key factor in thyroid cell proliferation regulation, prolonged stimulation of the cells during L-thyroxine withdrawal can be a causative factor for a re-growth. Our aim was to assess the degree of thyroid re-growth in the patients after total thyroidectomy due to DTC and its possible clinical implications.
Material and methods: 23 patients operated due to papillary and follicular thyroid cancer were included into the study. Biochemical determinations and ultrasound thyroid imaging were performed (TSH, Tg) during suppressive L-thyroxine therapy as well as 4-5 weeks after the withdrawal.
Results: The mean volume of thyroid tissue remnants increased after withdrawal for substantial 30.1%. The difference was extremely significant.
Conclusions: L-Thyroxine withdrawal in the patients after total thyroidectomy due to DTC can cause re-growth of the tissue remnants. The phenomenon may be of a clinical significance in the selected cases influencing therapeutic decisions. (Pol J Endocrinol 2008; 59 (2): 119-122)

Abstract


Introduction: The treatment-of-choice for differentiated thyroid carcinoma (DTC) is a total thyroidectomy with subsequent radioiodine therapy. In order to increase an iodine uptake in thyroid tissue remnants, the L-thyroxine withdrawal is required. It is recommended to achieve TSH levels higher than 25 mU/ml. As TSH is a known key factor in thyroid cell proliferation regulation, prolonged stimulation of the cells during L-thyroxine withdrawal can be a causative factor for a re-growth. Our aim was to assess the degree of thyroid re-growth in the patients after total thyroidectomy due to DTC and its possible clinical implications.
Material and methods: 23 patients operated due to papillary and follicular thyroid cancer were included into the study. Biochemical determinations and ultrasound thyroid imaging were performed (TSH, Tg) during suppressive L-thyroxine therapy as well as 4-5 weeks after the withdrawal.
Results: The mean volume of thyroid tissue remnants increased after withdrawal for substantial 30.1%. The difference was extremely significant.
Conclusions: L-Thyroxine withdrawal in the patients after total thyroidectomy due to DTC can cause re-growth of the tissue remnants. The phenomenon may be of a clinical significance in the selected cases influencing therapeutic decisions. (Pol J Endocrinol 2008; 59 (2): 119-122)
Get Citation

Keywords

differentiated thyroid cancer; total thyroidectomy; suppresive therapy; TSH; L-thyroxine; regrowth

About this article
Title

Influence of the endogene TSH stimulation of thyroid volume increase in the patients after total thyroidectomy due to differentiated thyroid cancer

Journal

Endokrynologia Polska

Issue

Vol 59, No 2 (2008)

Pages

119-122

Published online

2008-05-08

Bibliographic record

Endokrynologia Polska 2008;59(2):119-122.

Keywords

differentiated thyroid cancer
total thyroidectomy
suppresive therapy
TSH
L-thyroxine
regrowth

Authors

Leszek Pietz
Krzysztof Michałek
Ryszard Waśko
Marek Ruchała
Jerzy Sowiński

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl